(Total Views: 86)
Posted On: 05/23/2025 1:35:46 PM
Post# of 27540
BriaCell $BCTX impresses for #ASCO25 Phase 2 data shows survival and clinical benefit that meets or beats FDA-approved therapies in heavily pretreated MBC patients and no treatment-related discontinuations. https://globenewswire.com/news-release/2025/0...-2025.html #STOCKS #STOCKSTOBUY #INVESTORS #STOCKS #TRADER #BCTX @smallcapvoice
(0)
(0)
